Clinical Trials Logo

Varices clinical trials

View clinical trials related to Varices.

Filter by:
  • None
  • Page 1

NCT ID: NCT06392503 Recruiting - Liver Cirrhosis Clinical Trials

Noninvasive Diagnosis Model for High-risk Varices in Cirrhosis

NID-HRV
Start date: November 30, 2023
Phase:
Study type: Observational

This is an observational ambispective cohort study to validate the Baveno VI guideline and develop a new diagnostic model to screen high-risk varices (HRV) of liver cirrhosis using iLivTouch.

NCT ID: NCT05538546 Not yet recruiting - Cirrhosis Clinical Trials

Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients

CHESS2204
Start date: September 2022
Phase:
Study type: Observational

Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000 are considered to have very low risk of having varices requiring treatment, but whether these patients can be followed up by repetition of this criteria lacks sufficient evidence. This study aimed to assess the value of Baveno VI criteria for following up and monitoring of varices needing treatment in patients with compensated cirrhosis.

NCT ID: NCT05511766 Recruiting - Cirrhosis Clinical Trials

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Start date: November 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

NCT ID: NCT01287702 Recruiting - Varices Clinical Trials

Early Feeding Following Ligation of Acute Bleeding Varices

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The impact of feeding after endoscopic treatment of gastroesophageal varices has never been investigated. It is still unknown whether early feeding may increase early rebleeding in patients with acute esophageal variceal bleeding treated with EVL. It is customary for clinicians to institute fasting for 2 or 3 days after emergency EVL. This may be a safe approach to watch against early rebleeding. However, many patients would be fasting for a longer time and nutrition may be impaired, possibly resulting in aggravation of ascites. Thus, the investigators conduct a controlled study to evaluate whether early feeding have a bad impact on patients receiving emergency EVL or histoacryl injection for bleeding gastric varices.